



!fw

PATENT
ATTORNEY DOCKET NO. 04843/117002

Certificate of Mailing: Date of Deposit: 12/2/04

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Santa Zingariello
Printed name of person mailing correspondence

Santa Zingariello
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Renshaw et al.	Art Unit:	1632
Serial No.:	10/740,075	Examiner:	Matthew L. Fedowitz
Filed:	December 17, 2003	Customer No.:	21559
Title:	COMPOUNDS FOR THE NORMALIZATION OF THE SLEEP/WAKE CYCLE		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the

merits.

If there are any charges or any credits, please apply them to Deposit Account No.
03-2095.

Respectfully submitted,

Date: 02 December 2004



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/117002
	Serial No.	10/740,075
	Applicant	Renshaw et al.
	Filing Date	December 17, 2003
	Group	1623
	IDS Filed	December 2, 2004

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,027,017	05/31/1977	Hata et al.			
	4,048,316	09/13/1977	Penn			
	4,115,576	09/19/1978	Penn			
	4,704,361	11/03/1987	Miccoli et al.			
	5,278,176	01/11/1994	Lin			
	5,409,946	04/25/1995	Garvey et al.			
	5,472,958	12/05/1995	Gunn, Jr. et al.			
	5,691,320	11/25/1997	von Borstel et al.			
	5,919,789	07/06/1999	Dyke et al.			
	5,958,896	09/28/1999	Renshaw et al.			
	6,103,703	08/15/2000	Renshaw et al.			
	6,153,653	11/28/2000	Shashoua			
	2002/019364	02/14/2002	Renshaw			
	2003/220291	11/27/2003	Renshaw			
	2004/176316	09/09/2004	Renshaw et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	JP 08-183737	07/16/1996	Japan			
	0 188647 A1	07/30/1986	EPO			
	WO 00/06174	02/10/2000	WIPO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/117002
	Serial No.	10/740,075
	Applicant	Renshaw et al.
	Filing Date	December 17, 2003
	Group	1623
	IDS Filed	December 2, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Agnoli et al., "Efficacy of CDPcholine in Chronic Cerebral Vascular Diseases (CCVD)," <i>Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine</i> Elsevier 305-315 (1985).
	Alvarez et al., "Double-Blind Placebo-Controlled Study with Citicoline in APOE Genotyped Alzheimer's Disease Patients. Effects on Cognitive Performance, Brain Bioelectrical Activity and Cerebral Perfusion," <i>Methods Find Exp. Clin. Pharmacol.</i> (Abstract) 21:633-644 (1999).
	Babb et al., "Differential Effect of CDP-choline on Brain Cytosolic Choline Levels in Younger and Older Subjects as Measured by Proton Magnetic Resonance Spectroscopy," <i>Psychopharmacology</i> 127:88-94 (1996).
	Boudouresques et al., "Therapeutic Conduct in Light of a Cerebral Vascular Accident and the Use of CDP-Choline," <i>International Symposium: Brain Suffering and Precursors of Phospholipids</i> pp. 1-13 (1980).
	Brown et al., "CNS Complications of Cocaine Abuse: Prevalence, Pathophysiology, and Neuroradiology," <i>Am. J. Roentgenol.</i> 159:137-147 (1992).
	Centrone et al., "Use of Citicoline in High Dosages in Acute Cerebrovascular Disease," <i>Minerva Med.</i> (English Abstract) 77:371-373 (1986).
	Chang et al., "Neurochemical Alterations in Asymptomatic Abstinent Cocaine Users: A Proton Magnetic Resonance Spectroscopy Study," <i>Biol. Psychiatry</i> 42:1105-1114 (1997).
	Christensen et al., "Abnormal Cerebral Metabolism in Polydrug Abusers During Early Withdrawal: A ³¹ P MR Spectroscopy Study," <i>Magn. Reson. Med.</i> 35:658-663 (1996).
	Citicoline Sodium (CDP-Choline), <i>Investigator's Brochure</i> , Revised: April 1994 by Interneuron Pharmaceuticals, Inc.
	Cohen et al., "Decreased Brain Choline Uptake in Older Adults, An in vivo Proton Magnetic Resonance Spectroscopy Study" <i>JAMA</i> 274:902-907 (1995).
	English et al., "Elevated Frontal Lobe Cytosolic Choline Levels in Minimal or Mild AIDS Dementia Complex Patients: A Proton Magnetic Resonance Spectroscopy Study," <i>Biol. Psychiatry</i> 41:500-502 (1997).
	Fioravanti et al., "Cytidinediphosphocholine (CDP Choline) for Cognitive and Behavioural Disturbances Associated with Chronic Cerebral Disorders in the Elderly," <i>Cochrane Database Systems</i> (Abstract) 4:CD000269 (2000).
	Gallai et al., "Study of the P300 and Cerebral Maps in Subjects with Multi-Infarct Dementia Treated with Cytidine," <i>Psychopharmacology</i> 103:1-5 (1991).
	Galletti et al., "Biochemical Rationale for the Use of CDPcholine in Traumatic Brain Injury: Pharmacokinetics of the Orally Administered Drug," <i>J. Neural. Sci.</i> 103:S19-S25 (1991).
	Hoff et al., "Effects of Crack Cocaine on Neurocognitive Function," <i>Psychiatry Res.</i> 60:167-176 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/117002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/740,075
		Applicant	Renshaw et al.
		Filing Date	December 17, 2003
		Group	1623
		IDS Filed	December 2, 2004
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Jacobs et al., "Cocaine Abuse: Neurovascular Complications," <i>Radiology</i> 170:223-227 (1989).
	Kaufman et al., "Cocaine-Induced Cerebral Vasoconstriction Detected in Humans with Magnetic Resonance Angiography," <i>JAMA</i> 279:376-380 (1998).
	Kreek, "Opiate and Cocaine Addictions: Challenge for Pharmacotherapies," <i>Pharmacol. Biochem. Behav.</i> 57:551-569 (1997).
	Levin et al., "Improved Regional Cerebral Blood Flow in Chronic Cocaine Polydrug Users Treated with Buprenorphine," <i>J. Nucl. Med.</i> 36:1211-1215 (1995).
	London et al., "Cerebral Glucose Utilization in Human Heroin Addicts: Case Reports from a Positron Emission Tomographic Study," <i>Res. Commun. Subst. Abuse</i> 10:141-144 (1989).
	Lukacsco et al., "Modulation of the Vasoconstrictor Response to Adrenergic Stimulation by Nucleosides and Nucleotides," <i>J. Pharmacol. Exp. Ther.</i> 222:344-349 (1982).
	Lukas et al., "Effects of Short-Term Citicoline Treatment on Acute Cocaine Intoxication and Cardiovascular Effects," <i>Psychopharmacology</i> 157:163-167 (2001).
	Maas et al., "Functional Magnetic Resonance Imaging of Human Brain Activation During Cue-Induced Cocaine Craving," <i>Am. J. Psychiatry</i> 155:124-126 (1998).
	Malec et al., "Influence of Adenosinergic Drugs on Ethanol Withdrawal Syndrome in Rats," <i>Pol. J. Pharmacol.</i> 48:583-588 (1996).
	McCance, "Overview of Potential Treatment Medications for Cocaine Dependence," <i>NIDA Res. Monogr.</i> 175:36-72 (1997).
	Moglia et al., "Citicoline in Patients with Chronic Cerebrovascular Diseases (CCVD): Quantitative EEG Study," <i>Curr. Ther. Res.</i> 36:309-313 (1984).
	Monticone et al., "On the Therapeutic Use of Nucleosides, Cytidine and Uridine, in some Neurological Diseases," <i>Minerva Med.</i> 57:4348-4352 (1966).
	O'Rourke et al., "Effect of Chronic Cocaine Exposure on Carotid Artery Reactivity in Neonatal Rabbits," <i>Life Sci.</i> 59:119-130 (1996).
	Page et al., "Developmental Disorder Associated with Increased Cellular Nucleotidase Activity," <i>Proc. Natl. Acad. Sci. USA</i> 94:11601-11606 (1997).
	Peterson et al., "Neurovascular Complications of Cocaine Abuse," <i>J. Neuropsychiatry Clin. Neurosci.</i> 3:143-149 (1991).
	Radulovacki et al., "Adenosine Analogs and Sleep in Rats," <i>J. Pharmacol. Exp. Ther.</i> 228:268-274 (1984).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/117002
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>		Serial No.	10/740,075
		Applicant	Renshaw et al.
		Filing Date	December 17, 2003
		Group	1623
		IDS Filed	December 2, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Renshaw et al., "Short-term Treatment with Citicoline (CDP-choline) Attenuates some Measures of Craving in Cocaine-Dependent Subjects: A Preliminary Report," <i>Psychopharmacology</i> 142:132-138 (1999).
	Saligaut et al., "Circling Behaviour in Rats with Unilateral Lesions of the Nigrostriatum Induced by 6 - Hydroxydopamine: Changes Induced by Oral Administration of Cytidine-5'- Diphosphocholine," <i>Neuropharmacology</i> 26:1315-1319 (1987).
	Salvadorini et al., "Clinical Evaluation of CDP-choline (NICHOLIN®): Efficacy as Antidepressant Treatment," <i>Curr. Ther. Res.</i> 18:513-520 (1975).
	Satoh et al., "Involvement of Adenosine A _{2A} Receptor in Sleep Promotion," <i>Eur. J. Pharmacol.</i> 351:155-162 (1998).
	Scammell et al., "An Adenosine A _{2A} Agonist Increases Sleep and Induces Fos in Ventrolateral Preoptic Neurons," <i>Neuroscience</i> . 107:653-663 (2001).
	Secades et al., "CDP-Choline: Pharmacological and Clinical Review," <i>Meth. Find. Exp. Clin. Pharmacol.</i> 17(Suppl. B):1-54 (1995).
	Self, et al., "Opposite Modulation of Cocaine-Seeking Behavior by D ₁ - and D ₂ -like Dopamine Receptor Agonists," <i>Science</i> 271:1586-1589 (1996).
	Shekim et al., "S-Adenosyl-L-Methionine (SAM) in Adults with ADHD, RS: Preliminary Results from an Open Trial," <i>Psychopharmacol. Bull.</i> 26:249-253 (1990).
	Sholar et al., "Concurrent Pharmacokinetic Analysis of Plasma Cocaine and Adrenocorticotrophic Hormone in Men," <i>J. Clin. Endocrinol. Metab.</i> 83:966-968 (1998).
	Tazaki et al., "Treatment of Acute Cerebral Infarction with a Choline Precursor in a Multicenter Double-Blind Placebo-Controlled Study," <i>Stroke</i> 19:211-216 (1988).
	Teoh et al., "Acute Interactions of Buprenorphine with Intravenous Cocaine and Morphine: An Investigational New Drug Phase I Safety Evaluation," <i>J. Clin. Psychopharmacol.</i> 13:87-99 (1993).
	Tornos et al., "Effect of Oral CDP-Choline on Experimental Withdrawal Syndrome," <i>Arzneim.-Forsch./Drug Res.</i> 33:1018-1021 (1983).
	Warner et al., "Pharmacotherapy for Opioid and Cocaine Abuse," <i>Med. Clin. North Am.</i> 81:909-925 (1997).
	Weiss, "Metabolism and Actions of CDP-Choline as an Endogenous Compound and Administered Exogenously as Citicoline," <i>Life Sci.</i> 56:637-660 (1995).
	Wurtman et al., "Effect of Oral CDP-choline on Plasma Choline and Uridine Levels in Humans," <i>Biochem. Pharmacol.</i> 60:989-992 (2000).

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.</p>	